Mobile

A Phase III, Randomized, Open-label, Single-center Study to Evaluate the Safety and Immunogenicity of a FLUAD-H5N1 Influenza Vaccine in Adult Subjects Using Four Different Vaccination Schedules

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-003008-72

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the magnitude of antibody responses to two doses of FLUAD-H5N1 influenza vaccine, each containing 7.5µg of A/H5N1 antigen administered 1, 2, 3, or 6 weeks apart. To evaluate the safety and tolerability of two 0.5 mL intramuscular (IM) injections of FLUAD-H5N1 influenza vaccine containing 7.5µg of A/H5N1 influenza antigen.

Critère d'inclusion

  • Pandemic influenza

Liens